TAZVERIK Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tazverik, and when can generic versions of Tazverik launch?
Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-two patents protecting this drug.
This drug has three hundred and eighty-five patent family members in thirty-nine countries.
The generic ingredient in TAZVERIK is tazemetostat hydrobromide. One supplier is listed for this compound. Additional details are available on the tazemetostat hydrobromide profile page.
DrugPatentWatch® Generic Entry Outlook for Tazverik
Tazverik was eligible for patent challenges on January 23, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 19, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TAZVERIK?
- What are the global sales for TAZVERIK?
- What is Average Wholesale Price for TAZVERIK?
Summary for TAZVERIK
| International Patents: | 385 |
| US Patents: | 22 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 90 |
| Clinical Trials: | 15 |
| Patent Applications: | 301 |
| Drug Prices: | Drug price information for TAZVERIK |
| What excipients (inactive ingredients) are in TAZVERIK? | TAZVERIK excipients list |
| DailyMed Link: | TAZVERIK at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TAZVERIK
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TAZVERIK
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Genentech, Inc. | Phase 2 |
| Weill Medical College of Cornell University | Phase 2 |
| American Society of Clinical Oncology | Phase 1 |
Pharmacology for TAZVERIK
US Patents and Regulatory Information for TAZVERIK
TAZVERIK is protected by thirty-eight US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAZVERIK is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TAZVERIK
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Methods of treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
FDA Regulatory Exclusivity protecting TAZVERIK
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TAZVERIK
When does loss-of-exclusivity occur for TAZVERIK?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15350108
Patent: Method for treating cancer
Estimated Expiration: ⤷ Sign Up
Patent: 21204706
Patent: METHOD FOR TREATING CANCER
Estimated Expiration: ⤷ Sign Up
Patent: 24201171
Patent: METHOD FOR TREATING CANCER
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2017010166
Patent: método de tratamento de um tumor sólido, método de inibição da atividade, forma de dosagem oral para o tratamento de um tumor sólido, formulação farmacêutica sólida, processo para a preparação de uma formulação farmacêutica, e, composição farmacêutica sólida
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 67664
Patent: FORMULATIONS PHARMACEUTIQUES COMPRENANT DES INHIBITEURS DE L'HISTONE METHYLTRANSFERASE EZH2 HUMAIN (PHARMACEUTICAL FORMULATIONS COMPRISING INHIBITORS OF HUMAN HISTONE METHYLTRANSFERASE EZH2)
Estimated Expiration: ⤷ Sign Up
China
Patent: 7249591
Patent: 治疗癌症的方法 (Method for treating cancer)
Estimated Expiration: ⤷ Sign Up
Patent: 6650500
Patent: 治疗癌症的方法 (Methods of treating cancer)
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 1791095
Patent: СПОСОБ ЛЕЧЕНИЯ РАКА
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 20916
Patent: MÉTHODE DE TRAITEMENT DU CANCER (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷ Sign Up
Patent: 72742
Patent: EPZ-6438 POUR UTILISATION DANS UNE MÉTHODE DE TRAITEMENT DU CANCER (EPZ-6438 FOR USE IN A METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 62159
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 2182
Patent: שיטות לטיפול בסרטן (Method for treating cancer)
Estimated Expiration: ⤷ Sign Up
Patent: 6080
Patent: שיטות לטיפול בסרטן (Method for treating cancer)
Estimated Expiration: ⤷ Sign Up
Patent: 4252
Patent: שיטות לטיפול בסרטן (Method for treating cancer)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 29684
Estimated Expiration: ⤷ Sign Up
Patent: 85810
Estimated Expiration: ⤷ Sign Up
Patent: 17537899
Patent: 癌を処置する方法
Estimated Expiration: ⤷ Sign Up
Patent: 21073241
Patent: 癌を処置する方法 (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷ Sign Up
Patent: 23062189
Patent: 癌を処置する方法
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 17006089
Patent: METODO PARA TRATAR EL CANCER. (METHOD FOR TREATING CANCER.)
Estimated Expiration: ⤷ Sign Up
Patent: 21006734
Patent: METODO PARA TRATAR EL CANCER. (METHOD FOR TREATING CANCER.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 1696
Patent: Method for treating cancer
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201703806X
Patent: METHOD FOR TREATING CANCER
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 20916
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2338802
Estimated Expiration: ⤷ Sign Up
Patent: 2644844
Estimated Expiration: ⤷ Sign Up
Patent: 170103768
Patent: 암을 치료하기 위한 방법 (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷ Sign Up
Patent: 210156840
Patent: 암을 치료하기 위한 방법 (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷ Sign Up
Patent: 240035908
Patent: 암을 치료하기 위한 방법 (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 47819
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TAZVERIK around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20220139453 | 인간 ＥＺＨ2의 억제제 및 이의 사용 방법 (2 INHIBITORS OF HUMAN EZH2 AND METHODS OF USE THEREOF) | ⤷ Sign Up |
| Slovenia | 2697199 | ⤷ Sign Up | |
| Portugal | 3184523 | ⤷ Sign Up | |
| South Korea | 20240035908 | 암을 치료하기 위한 방법 (METHOD FOR TREATING CANCER) | ⤷ Sign Up |
| Australia | 2022242157 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | ⤷ Sign Up |
| Russian Federation | 2014145544 | СОЛЕВАЯ ФОРМА ИНГИБИТОРА ГИСТОН-МЕТИЛТРАНСФЕРАЗЫ EZH2 ЧЕЛОВЕКА | ⤷ Sign Up |
| South Korea | 20170070140 | 암을 치료하기 위한 방법 (METHOD FOR TREATING CANCER) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
